United States Osteoporosis Drugs Market Report 2017

October 2017 | 102 pages | ID: U5CDB39F291WEN
QYResearch

Abstracts

In this report, the United States Osteoporosis Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Osteoporosis Drugs in these regions, from 2012 to 2022 (forecast).

United States Osteoporosis Drugs market competition by top manufacturers/players, with Osteoporosis Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Eli Lilly
• Novartis
• Pfizer
• Amgen
• Merck
• Novo Nordisk
• Actavis
• Roche
• Upsher-Smith
• Sebela Pharma

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Bone Absorption-Inhibitor Drugs
• Bone Formation-Acceleration Drugs

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Osteoporosis Drugs for each application, including

• Male
• Female

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Osteoporosis Drugs Market Report 2017

1 OSTEOPOROSIS DRUGS OVERVIEW

1.1 Product Overview and Scope of Osteoporosis Drugs
1.2 Classification of Osteoporosis Drugs by Product Category
  1.2.1 United States Osteoporosis Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Osteoporosis Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Bone Absorption-Inhibitor Drugs
  1.2.4 Bone Formation-Acceleration Drugs
1.3 United States Osteoporosis Drugs Market by Application/End Users
  1.3.1 United States Osteoporosis Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Male
  1.3.3 Female
1.4 United States Osteoporosis Drugs Market by Region
  1.4.1 United States Osteoporosis Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Osteoporosis Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Osteoporosis Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Osteoporosis Drugs Status and Prospect (2012-2022)
  1.4.5 New England Osteoporosis Drugs Status and Prospect (2012-2022)
  1.4.6 The South Osteoporosis Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Osteoporosis Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Osteoporosis Drugs (2012-2022)
  1.5.1 United States Osteoporosis Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Osteoporosis Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES OSTEOPOROSIS DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Osteoporosis Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Osteoporosis Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Osteoporosis Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Osteoporosis Drugs Market Competitive Situation and Trends
  2.4.1 United States Osteoporosis Drugs Market Concentration Rate
  2.4.2 United States Osteoporosis Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Osteoporosis Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES OSTEOPOROSIS DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Osteoporosis Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Osteoporosis Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Osteoporosis Drugs Price by Region (2012-2017)

4 UNITED STATES OSTEOPOROSIS DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Osteoporosis Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Osteoporosis Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Osteoporosis Drugs Price by Type (2012-2017)
4.4 United States Osteoporosis Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES OSTEOPOROSIS DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Osteoporosis Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Osteoporosis Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES OSTEOPOROSIS DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Eli Lilly
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Osteoporosis Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Eli Lilly Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Novartis
  6.2.2 Osteoporosis Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Novartis Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Pfizer
  6.3.2 Osteoporosis Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Pfizer Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Amgen
  6.4.2 Osteoporosis Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Amgen Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Merck
  6.5.2 Osteoporosis Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Merck Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Novo Nordisk
  6.6.2 Osteoporosis Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Novo Nordisk Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Actavis
  6.7.2 Osteoporosis Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Actavis Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Roche
  6.8.2 Osteoporosis Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Roche Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Upsher-Smith
  6.9.2 Osteoporosis Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Upsher-Smith Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Sebela Pharma
  6.10.2 Osteoporosis Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Sebela Pharma Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 OSTEOPOROSIS DRUGS MANUFACTURING COST ANALYSIS

7.1 Osteoporosis Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Osteoporosis Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Osteoporosis Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Osteoporosis Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Osteoporosis Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Osteoporosis Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Osteoporosis Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Osteoporosis Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Osteoporosis Drugs
Figure United States Osteoporosis Drugs Market Size (K Units) by Type (2012-2022)
Figure United States Osteoporosis Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Bone Absorption-Inhibitor Drugs Product Picture
Figure Bone Formation-Acceleration Drugs Product Picture
Figure United States Osteoporosis Drugs Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Osteoporosis Drugs by Application in 2016
Figure Male Examples
Table Key Downstream Customer in Male
Figure Female Examples
Table Key Downstream Customer in Female
Figure United States Osteoporosis Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Osteoporosis Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Osteoporosis Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Osteoporosis Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Osteoporosis Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Osteoporosis Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Osteoporosis Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Osteoporosis Drugs Sales (K Units) and Growth Rate (2012-2022)
Figure United States Osteoporosis Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Osteoporosis Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Osteoporosis Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Osteoporosis Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Osteoporosis Drugs Sales Share by Players/Suppliers
Figure 2017 United States Osteoporosis Drugs Sales Share by Players/Suppliers
Figure United States Osteoporosis Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Osteoporosis Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Osteoporosis Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Osteoporosis Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Osteoporosis Drugs Revenue Share by Players/Suppliers
Table United States Market Osteoporosis Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Osteoporosis Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Osteoporosis Drugs Market Share of Top 3 Players/Suppliers
Figure United States Osteoporosis Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Osteoporosis Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Osteoporosis Drugs Product Category
Table United States Osteoporosis Drugs Sales (K Units) by Region (2012-2017)
Table United States Osteoporosis Drugs Sales Share by Region (2012-2017)
Figure United States Osteoporosis Drugs Sales Share by Region (2012-2017)
Figure United States Osteoporosis Drugs Sales Market Share by Region in 2016
Table United States Osteoporosis Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Osteoporosis Drugs Revenue Share by Region (2012-2017)
Figure United States Osteoporosis Drugs Revenue Market Share by Region (2012-2017)
Figure United States Osteoporosis Drugs Revenue Market Share by Region in 2016
Table United States Osteoporosis Drugs Price (USD/Unit) by Region (2012-2017)
Table United States Osteoporosis Drugs Sales (K Units) by Type (2012-2017)
Table United States Osteoporosis Drugs Sales Share by Type (2012-2017)
Figure United States Osteoporosis Drugs Sales Share by Type (2012-2017)
Figure United States Osteoporosis Drugs Sales Market Share by Type in 2016
Table United States Osteoporosis Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Osteoporosis Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Osteoporosis Drugs by Type (2012-2017)
Figure Revenue Market Share of Osteoporosis Drugs by Type in 2016
Table United States Osteoporosis Drugs Price (USD/Unit) by Types (2012-2017)
Figure United States Osteoporosis Drugs Sales Growth Rate by Type (2012-2017)
Table United States Osteoporosis Drugs Sales (K Units) by Application (2012-2017)
Table United States Osteoporosis Drugs Sales Market Share by Application (2012-2017)
Figure United States Osteoporosis Drugs Sales Market Share by Application (2012-2017)
Figure United States Osteoporosis Drugs Sales Market Share by Application in 2016
Table United States Osteoporosis Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Osteoporosis Drugs Sales Growth Rate by Application (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Eli Lilly Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Eli Lilly Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Novartis Basic Information List
Table Novartis Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novartis Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Novartis Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Novartis Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Pfizer Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Pfizer Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Amgen Basic Information List
Table Amgen Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Amgen Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Amgen Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Amgen Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Merck Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Merck Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Merck Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novo Nordisk Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Novo Nordisk Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Novo Nordisk Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Actavis Basic Information List
Table Actavis Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Actavis Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Actavis Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Actavis Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Roche Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Roche Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Roche Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Upsher-Smith Basic Information List
Table Upsher-Smith Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Upsher-Smith Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Upsher-Smith Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Upsher-Smith Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Sebela Pharma Basic Information List
Table Sebela Pharma Osteoporosis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sebela Pharma Osteoporosis Drugs Sales Growth Rate (2012-2017)
Figure Sebela Pharma Osteoporosis Drugs Sales Market Share in United States (2012-2017)
Figure Sebela Pharma Osteoporosis Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Osteoporosis Drugs
Figure Manufacturing Process Analysis of Osteoporosis Drugs
Figure Osteoporosis Drugs Industrial Chain Analysis
Table Raw Materials Sources of Osteoporosis Drugs Major Players/Suppliers in 2016
Table Major Buyers of Osteoporosis Drugs
Table Distributors/Traders List
Figure United States Osteoporosis Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Osteoporosis Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Osteoporosis Drugs Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Osteoporosis Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Osteoporosis Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Osteoporosis Drugs Sales Volume (K Units) Forecast by Type in 2022
Table United States Osteoporosis Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Osteoporosis Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Osteoporosis Drugs Sales Volume (K Units) Forecast by Application in 2022
Table United States Osteoporosis Drugs Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Osteoporosis Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Osteoporosis Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Osteoporosis Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources